Key Segmentation
By Device Type
-
Insulin Pens
-
Insulin Pumps
-
Insulin Syringes
-
Continuous Glucose Monitors
-
Others
By Insulin Type
-
Long-Acting Insulin
-
Rapid-Acting Insulin
-
Short-Acting Insulin
-
Intermediate-Acting Insulin
-
Premixed Insulin
By Treatment Type
-
Insulin Therapy
-
Automated Insulin Delivery Systems
-
Immunotherapy
-
Islet Cell Therapy
By End User
-
Home Care
-
Hospitals and Clinics
-
Research Institutes
By Distribution Channel
-
Retail Pharmacies
-
Online Pharmacies
-
Hospital Pharmacies
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Novo Nordisk, Eli Lilly and Company, Sanofi, Biocon Biologics, MiniMed, Dexcom, Abbott, Insulet, Tandem Diabetes Care, Beta Bionics, Sequel Med Tech, Senseonics, mylife Diabetes Care, MannKind, Tonghua Dongbao, Gan & Lee Pharmaceuticals, Julphar and Roche Diabetes Care.
Key opportunities include disease-modifying immunotherapy, islet cell therapy, early autoantibody screening, closed-loop insulin delivery and insulin biosimilars in emerging markets.
Rising diagnosed prevalence and the adoption of continuous glucose monitoring and automated insulin delivery are the main growth factors.
By Device Type, the Insulin Pens segment dominated the market in 2025 with an estimated 46.65% share, supported by ease of use, accurate dosing and wide availability.
North America dominated the market with a share of 41.53% in 2025, driven by early technology adoption, high diagnosis rates and broad insurance coverage.